by Helena Cowley | Feb 17, 2021 | News, Press Release
GAINESVILLE, FL, USA, February 18, 2021 /EINPresswire.com/ — Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an underserved kidney disease indication, today announced two additions to its...
by Helena Cowley | Sep 23, 2020 | News, Press Release
Recognized as Early Stage Company with Ground-breaking TechnologyWinning Buzz of BIO gives us an additional boost going into BIO Investor Forum Digital where we will present this opportunity to potential new investors”— Helena CowleyGAINESVILLE, FL, USA, September 23,...
by Helena Cowley | Sep 10, 2020 | News, Press Release
A Prospective, Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study Using a Proprietary Orally Administered Oxalate Decarboxylase (OxDC)GAINESVILLE, FLA, USA, September 10, 2020 /EINPresswire.com/ — Oxidien Pharmaceuticals, a clinical-stage...
by Helena Cowley | Jul 9, 2020 | News, Press Release
GAINESVILLE, FL, USA, July 9, 2020 /EINPresswire.com/ — Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an underserved kidney disease indication, today announced three additions to its...
by Helena Cowley | Jun 26, 2020 | News, Press Release
Oxidien in the top 3 at Life Science Nation’s RESI Innovation Challenge. Read More
